Actelion Ltd (ALIOF) 174.2800 $ALIOF Dr. Reddy's (RDY)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actelion Ltd (ALIOF) 174.2800 $ALIOF

Dr. Reddy's (RDY) Q1 Earnings and Revenues Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:10AM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2017 earnings per American Depositary Share of 11 cents, down 79.6% from the year-ago quarter.
RDY: 44.37 (+0.26), BMY: 75.99 (+0.93)

Seattle Genetics' (SGEN) Loss Narrower than Expected in Q2
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:06AM CDT
Seattle Genetics (SGEN) reported a loss of 23 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 33 cents.
SGEN: 46.69 (+2.92), BMY: 75.99 (+0.93)

After GILD Earnings, Which Biomed Stock is Best Right Now?
Ryan McQueeney - Zacks Investment Research - Tue Jul 26, 3:55PM CDT
For many investors, Gilead is the go-to stock in the biomed industry. However, with revenues looking sluggish this year, these three Zacks Rank #1 (Strong Buy) stocks might end up being a better bet.
INVA: 11.90 (+0.46), GILD: 81.55 (+0.50), ANIP: 60.35 (+0.86)

Actelion (ALIOF) Beats Q2 Earnings & Revenues, View Up
Zacks Equity Research - Zacks Investment Research - Fri Jul 22, 12:13PM CDT
Actelion (ALIOF) reported second-quarter 2016 earnings of $2.13 per American Depository Receipt, up from the year-ago figure of $1.60.
INVA: 11.90 (+0.46), SNY: 42.15 (+0.04), NKTR: 15.23 (+0.08)

Medical Stocks to Post Earnings This Week: ABT, BIIB, ALIOF
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 9:06AM CDT
Medical is one of the few sectors that are poised to report earnings growth this quarter. While the sector's second-quarter earnings are projected to improve 0.5%, revenues are expected to grow 7.7%.
BIIB: 287.90 (+0.86), ABT: 43.49 (-0.11), NVS: 82.56 (-0.46)

3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 17.81 (+0.47), GILD: 81.55 (+0.50), MRK: 58.40 (+0.04), UTHR: 113.25 (+0.80)

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved
Globe Newswire - Wed May 04, 5:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 33.54 (+0.10), UTHR: 113.25 (+0.80), AEGR: 1.44 (unch)

Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio
Globe Newswire - Thu Apr 21, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Clovis Hits 52-week Low Post Rociletinib Briefing Documents
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 2:45PM CDT
Clovis Oncology's (CLVS) shares touched a 52-week low with the FDA raising concerns related to the lung cancer treatment, rociletinib, in its briefing documents.
EBS: 33.54 (+0.10), CLVS: 14.27 (+0.31), ANIK: 52.03 (+0.20)

Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 3:40PM CDT
Ionis Pharmaceuticals' (IONS) shares plunged 11% after the FDA placed a clinical hold on the phase III CARDIO-TTR study on IONIS-TTRRx.
BIIB: 287.90 (+0.86), GSK: 44.91 (+0.75), IONS: 28.60 (+0.41)

Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.61 (unch), SCMP: 11.85 (+0.32), ICPT: 164.50 (+4.91)

Illumina Unveils BaseSpace Suite, Boosts Precision Medicine
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 12:55PM CDT
Illumina, Inc. (ILMN) recently launched its BaseSpace Informatics suite to facilitate precision medicine and genomics research.
ILMN: 162.27 (+12.17), AMAG: 26.85 (+1.90), ANIK: 52.03 (+0.20)

Seres Therapeutics (MCRB) in Focus: Stock Up 5.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:35AM CDT
Seres Therapeutics, Inc. (MCRB) was a big mover last session, as the company saw its shares rise around 6% on the day.
MCRB: 35.15 (+0.27)

Ironwood Slumps, Halts Development of Gastroparesis Drug
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:10AM CDT
Ironwood Pharmaceuticals (IRWD) plans to discontinue the development of IW-9179 for diabetic gastroparesis after unfavorable phase IIa study results; shares fall.
IRWD: 14.47 (+0.32), EBS: 33.54 (+0.10), AMAG: 26.85 (+1.90)

Actelion issues invitation to 2016 Annual General Meeting of Shareholders
Globe Newswire - Wed Apr 06, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2016 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

AbbVie Up, Wins CHMP Backing for Humira's Expanded Use
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 10:20AM CDT
AbbVie Inc. (ABBV) announced that the EMA's CHMP has rendered an opinion in favor of expanding Humira's label in the EU.
EBS: 33.54 (+0.10), ABBV: 64.70 (+0.25), AMAG: 26.85 (+1.90)

Abeona Therapeutics (ABEO) Jumps: Stock Rises 6.4%
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:40AM CDT
Abeona Therapeutics Inc. (ABEO) saw its shares rise above 6% in the last trading session.
ABEO: 2.48 (-0.06)

Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 3:10PM CDT
Bristol-Myers' (BMY) Opdivo gets CHMP backing for label expansion of Opdivo in combination with Yervoy for advanced (unresectable or metastatic) melanoma.
AMAG: 26.85 (+1.90), BMY: 75.99 (+0.93), ANIK: 52.03 (+0.20)

Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 2:40PM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi's atopic dermatitis candidate dupilumab scores in phase III studies; shares up.
AMAG: 26.85 (+1.90), SNY: 42.15 (+0.04), REGN: 409.63 (+11.36)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 65

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 29

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 65

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 53

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 164

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 40

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 59

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading

Top 5 Most Recently Viewed Articles

Synovus Appoints New Chattanooga Market Leader for Growth

Updated Category News Views 502

Synovus Appoints Jim Vaughn as Chattanooga Market Executive Synovus has recently made headlines by appointing Jim Vaughn as the new Chattanooga market executive. He brings a wealth of experience and has a solid background in the financial sector, joining from Mauldin & Jenkins, where he honed his skills over a significant tenure. Leadership Role and Responsibilities In...

Continue Reading
Navigating Recruitment Trends in Maritime and Oil & Gas for 2025

Updated Category News Views 85

Trends Shaping Recruitment in the Maritime and Oil & Gas Industries Core Group Resources stands at the forefront of talent acquisition, guiding businesses toward sustainable growth by effectively identifying and nurturing the right talent. As we approach 2025, the company has unveiled a comprehensive analysis detailing the pivotal trends that will influence recruitment...

Continue Reading
Disney and Netflix Stocks Dip Amid Warner Bros. Merger News

Updated Category News Views 430

Disney and Netflix Stocks Experience a Decline Securities of Walt Disney Co (NYSE: DIS) and Netflix Inc (NASDAQ: NFLX) are witnessing a downward trend, likely influenced by recent reports concerning a significant business maneuver involving Warner Bros. Discovery Inc (NASDAQ: WBD). Speculation arises that a coalition led by Paramount Skydance Corp (NASDAQ: PSKY) is...

Continue Reading
Alpine Income Property Trust Launches New Preferred Stock Offering

Updated Category News Views 136

Alpine Income Property Trust Announces Public Offering Alpine Income Property Trust, Inc. (NYSE: PINE) has officially announced the launch of its public offering for the Series A Cumulative Redeemable Preferred Stock, which has a liquidation preference of $25.00 per share. This initiative reflects the company’s strategic approach to expanding its capital base and...

Continue Reading
Civitas Capital Strengthens Team with New Regional Director

Updated Category News Views 127

Civitas Capital Welcomes Rishabh Gandhi Civitas Capital is thrilled to announce a significant addition to our team: Rishabh Gandhi, who joins us as Regional Director for India and the Middle East. With over nine years of invaluable experience in the EB-5 investment industry, Rishabh brings a wealth of expertise, strategic insight, and an established network of...

Continue Reading